Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 6/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | CLPP | Q16740 | 1/20 | 0.41 |
| ▸ | PRLHR | P49683 | 2/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3297765 | 0.93 | PRLHR (0.47) | P2RX3TLR9MAPTLMNASMN1; SMN2 | |
| SCHEMBL22410813 | 0.90 | P2RX3 (0.46) | P2RX3TLR9MAPTLMNASMN1; SMN2 | |
| SCHEMBL3298016 | 0.83 | PRLHR (0.47) | MAPTSMN1; SMN2PRLHRSLC2A1 | |
| SCHEMBL3298271 | 0.82 | PRLHR (0.47) | MAPTKDM4ECLPPPRLHR | |
| SCHEMBL29579743 | 0.81 | ALDH1A1 (0.46) | P2RX3MAPTKDM4EPARP1TNKS2 | |
| SCHEMBL28669319 | 0.81 | CLPP (0.44) | MAPTLMNATP53CLPPPRLHR | |
| SCHEMBL3301167 | 0.79 | PRLHR (0.48) | MAPTCLPPPRLHR | |
| SCHEMBL29579602 | 0.79 | MAPT (0.48) | P2RX3MAPTLMNASMN1; SMN2TP53 | |
| SCHEMBL22424056 | 0.79 | CLPP (0.56) | P2RX3MAPTLMNASMN1; SMN2KDM4E | |
| SCHEMBL3297764 | 0.77 | PRLHR (0.70) | MAPTCLPPPRLHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232282-B2 | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-20100093771-A1 | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2078719-A1 | COMPOUND HAVING BICYCLIC PYRIMIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093771-A1 | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same | GART, MGAT2, MGAT1 | P2RX3 1321/4885TLR9 1181/4885MAPT 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.